You are here:

Archived: Nicotinic acid modified release tablets (Niaspan®)


Following a full submission.

Niaspan is not recommended for use within NHS Scotland for the treatment of primary hypercholesterolaemia and mixed dyslipidaemia.

Limited information comparing Niaspan with standard release nicotinic acid tablets showed similar efficacy in improving lipid parameters and a similar adverse-effect profile. However, there is a lack of information from prospective, double-blind trials comparing Niaspan with statins, fibrates and in combination with other lipid-lowering agents.

Drug Details

Drug Name: Nicotinic acid modified release tablets (Niaspan®)
SMC Drug ID: 93/04
Manufacturer: Merck Serono Ltd
Indication: Dyslipidaemia
BNF Category:
Sub Category: 2.12 Lipid-regulating drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 April 2004

Current Advice

Resubmission 13 February 2006

Archived Advice

Resubmission 10 January 2005